Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

Fujian Cancer Hospital: Clinical Trials & FDA Approval Profile

Fujian Cancer Hospital (Global / Institutional) sponsors 103 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 49 active protocols (16 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)1.0%
Median Closed Enrollment vs National (145 pts)95 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fujian Cancer Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)103
Active Pipeline (Recruiting Now)49 (16)
Completed vs Stopped Early5 / 1 (1.0%)
Median Closed Actual Enrollment95 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fujian Cancer Hospital
Hospital Research SiteLocationShared Protocols
Fujian Cancer HospitalFuzhou, Fujian39
The First Affiliated Hospital of Xiamen UniversityXiamen, Fujian2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fujian Cancer Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07256236SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Fujian Cancer Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI